Epco, Zanu, Ritux for R/R FL or MZL
Recruiting · Phase 2 · NCT06563596
Conditions: Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
At a glance
- Research payments reported, 2025
- $226,046
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 71
About the trial
- Sponsor
- Reid Merryman, MD (with BeiGene, Genmab)
- Tested
- Zanubrutinib (drug), Rituximab (drug), Epcoritamab (drug)
- Dates
- Started 2025-01-21; completion 2032-03-01
- Results posted
- Not yet
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $226,046 in research payments for this study in 2025 (3 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $226,046
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.